At a glance
ClinicalIndex Comparison Record- ✓Female age 20-50 years old
- ✓Planned abdominal myomectomy for symptomatic uterine fibroids
- ✕Contraindication to misoprostol or vasopressin
- ✕Personal history of cardiac disease
- ✕Personal history of pulmonary disease
- ✕Prior myomectomy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy
In Brief
A Phase 4 clinical trial evaluating Misoprostol 200Mcg Tab and Placebo for Myomectomy; Surgical Blood Loss. Completed, enrolled 18 participants across 3 sites.
Detailed Summary
Purpose is to identify if misoprostol in addition to local vasopressin decreases blood loss when compared to vasopressin alone, which is our current practice at this time. The study will be double-blinded with neither the patient nor the researcher knowing whether the placebo or the misoprostol was given. We will monitor patients for decrease in hemoglobin and hematocrit, need for transfusion, and operative time among other measures of perioperative morbidity to see if the addition of misoprostol makes a significant difference. We will also observe patients to see if there are any side effects of misoprostol that make its use undesirable.
Study Details
Timeline
Interventions
4 tablets will be inserted rectally